As therapeutic modalities evolve, so do the challenges and methodologies associated with maintaining and verifying cleanroom ...

Developing orphan drugs involves navigating intricate regulatory landscapes, financial risks, and limited clinical data. To ...

With only about $1.6 billion in debt in December 2024 compared with $0.3 billion in cash and investments, Waters maintains a financially flexible balance sheet with net leverage around 1 time. Waters ...

The facility, which will produce cell therapies used to treat cancer and auto immune diseases, creates 150 jobs for highly ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company’s Chief Financial ...

Vertex Pharmaceuticals (VRTX) and Neurocrine Biosciences (NBIX) shares are moving sharply after their respective earnings ...

BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical ...

Board Member Dr. Karen Smith to serve as Interim Chief Medical OfficerPHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Context ...

Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation, ...

In the vehicles’ strongest showing since early 2022, there were eight new SPACs from April 28 through May 5. Of those eight, ...

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 6.69%, which has investors questioning if this is right time to buy.